Impairs alertness and motor coordination including morning impairment. Risk increases with dose and if used with other central nervous system depressants.
- TRADE NAME: Dayvigo (Eisai)
- INDICATIONS: Adult patients with insomnia
- CLASS: Orexin receptor antagonist
- HALF-LIFE: 17–19 hours
- FDA APPROVAL DATE: 12/20/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bosentan, Carbamazepine, Chlorzoxazone, Clarithromycin, CYP3A inhibitors and inducers, Efavirenz, Etravirine, Fluconazole, Itraconazole, Modafinil, Ranitidine, Rifampin, St John's Wort, Verapamil - PREGNANCY: No available data in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 06/07/2024
